logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Fate Therapeutics, Inc.


USPTO Granted Patents = 48



Trademarks = 6

Forward Citations = 171

Loading Chart...
Loading Chart...

36 inventors (with patents filed for the assignee):

goldMedal Bahram Valamehr (34 out of 34 patents)

silverMedal Ryan Bjordahl (18 out of 18 patents)

bronzeMedal Tom Tong Lee (12 out of 12 patents)

4.  Raedun Clarke (11 out of 11 patents)

5.  Ramzey Abujarour (9 out of 9 patents)

6.  Peter Flynn (9 out of 9 patents)

7.  Betsy Rezner (8 out of 8 patents)

8.  David Robbins (7 out of 7 patents)

9.  Eigen Peralta (7 out of 7 patents)

10.  Jonathan Rosen (6 out of 6 patents)

11.  John D Mendlein (5 out of 86 patents)

12.  Jode Goodridge (5 out of 5 patents)

13.  Daniel D Shoemaker (5 out of 26 patents)

14.  Ian Hardy (4 out of 5 patents)

15.  Megan Robinson (4 out of 4 patents)


Core Competencies:
Immunotherapies
iPSC Derived Effector Cells
Hematopoietic Cell Differentiation
Ground State Pluripotency
Chimeric Antigen Receptor
Genomic Engineering
Cell Culture Platforms
Stem Cell Composition
Cell Potency Assay
Single Cell Sorting
Wnt Compositions
Therapeutic Uses

48 patents:

1. 12435123 - Immunotherapies using enhanced iPSC derived effector cells (2025-10-07),
2. 12419870 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-09-23),
3. 12415989 - Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs (2025-09-16),
4. 12410403 - Methods and compositions for inducing hematopoietic cell differentiation (2025-09-09),
5. 12398373 - Enhanced immune effector cells and use thereof (2025-08-26),
6. 12385012 - Methods and compositions for inducing hematopoietic cell differentiation (2025-08-12),
7. 12351831 - Platform for the induction and maintenance of ground state pluripotency (2025-07-08),
8. 12281329 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-04-21),
9. 12275955 - Combining iPSC derived effector cell types for immunotherapy use (2025-04-14),
10. 12264322 - Minimal volume reprogramming of mononuclear cells (2025-04-01),
11. 12247226 - Cellular reprogramming using temporal and transient plasmid vector expression system (2025-03-11),
12. 12203098 - Cells having solid tumor targeting backbone and use thereof (2025-01-21),
13. 12173274 - Enhanced immune effector cells and use thereof (2024-12-24),
14. 12122846 - Chimeric antigen receptor for tumor targeting (2024-10-22),
15. 12036241 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2024-07-16),
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. Their goal is to harness the power of stem cells and cellular reprogramming to create innovative therapies that can improve patient outcomes. With a focus on off-the-shelf, multi-functional cell products, Fate Therapeutics aims to bring transformative treatments to patients in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

48 Patents

#123 in San Diego, CA

#1,667 in California

#7,027 in US

#14,122 in the World

...
San Diego, CA, United States of America

Fate Therapeutics, Inc.

Forward Citations = 171

36 inventors:

goldMedal Bahram Valamehr (34 out of 34 patents)

silverMedal Ryan Bjordahl (18 out of 18 patents)

bronzeMedal Tom Tong Lee (12 out of 12 patents)

4.  Raedun Clarke (11 out of 11 patents)

5.  Ramzey Abujarour (9 out of 9 patents)

Please report any incorrect information to support@idiyas.com
Loading…